Literature DB >> 11206313

Use of ursodeoxycholic acid in liver diseases.

D Kumar1, R K Tandon.   

Abstract

Ursodeoxycholic acid is currently the only established drug for the treatment of chronic cholestatic liver diseases. It has cytoprotective, anti-apoptotic, membrane stabilizing, anti-oxidative and immunomodulatory effects. Prolonged administration of ursodeoxycholic acid in patients with primary biliary cirrhosis (PBC) is associated with survival benefit and a delaying of liver transplantation. There is evidence that it might even prevent progression of the histologic stage of PBC. It also has a beneficial effect on primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, liver disease associated with cystic fibrosis, chronic graft versus host disease, total parenteral nutrition associated cholestasis and various pediatric cholestatic liver diseases. In the present review the current knowledge about the mechanisms of the action and role of ursodeoxycholic acid in the treatment of various liver diseases has been discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206313     DOI: 10.1046/j.1440-1746.2001.02376.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

Review 1.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

2.  High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.

Authors:  M H Imam; E Sinakos; A A Gossard; K V Kowdley; V A C Luketic; M Edwyn Harrison; T McCashland; A S Befeler; D Harnois; R Jorgensen; J Petz; J Keach; A C DeCook; F Enders; K D Lindor
Journal:  Aliment Pharmacol Ther       Date:  2011-09-29       Impact factor: 8.171

3.  Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.

Authors:  Jian-Gao Fan; Lan Zhong; Li-Yan Tia; Zheng-Jie Xu; Min-Sheng Li; Guo-Liang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 4.  Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.

Authors:  Valerio Nobili; Arun J Sanyal
Journal:  J Gastroenterol       Date:  2011-10-08       Impact factor: 7.527

5.  Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials.

Authors:  Mario Simental-Mendía; Adriana Sánchez-García; Luis E Simental-Mendía
Journal:  Br J Clin Pharmacol       Date:  2020-04-27       Impact factor: 4.335

6.  A novel liver-targeted nitric oxide donor UDCA-Thr-NO protects against cirrhosis and portal hypertension.

Authors:  Jialin Sun; Menghua Li; Shiyong Fan; Zhongwu Guo; Bohua Zhong; Xueyuan Jin; Weiguo Shi
Journal:  Am J Transl Res       Date:  2018-02-15       Impact factor: 4.060

7.  Induction of avian musculoaponeurotic fibrosarcoma proteins by toxic bile acid inhibits expression of glutathione synthetic enzymes and contributes to cholestatic liver injury in mice.

Authors:  Heping Yang; Kwangsuk Ko; Meng Xia; Tony W H Li; Pilsoo Oh; Jiaping Li; Shelly C Lu
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

Review 8.  Glutathione synthesis.

Authors:  Shelly C Lu
Journal:  Biochim Biophys Acta       Date:  2012-09-17

Review 9.  S-adenosylmethionine in liver health, injury, and cancer.

Authors:  Shelly C Lu; José M Mato
Journal:  Physiol Rev       Date:  2012-10       Impact factor: 37.312

10.  Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications.

Authors:  Heping Yang; Komal Ramani; Meng Xia; Kwang Suk Ko; Tony W H Li; Pilsoo Oh; Jiaping Li; Shelly C Lu
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.